Ulwazi olwengeziwe ― Zulu

Urticaria ivamise ukuvezwa nama-welts aphakanyisiwe alume kakhulu. Ngezinye izikhathi kuhambisana nokuvuvukala kwezicubu ezingaphansi. Ukwelashwa ngokuyinhloko kuhilela ukugwema izibangeli, uma zaziwa. Imithi yomugqa wokuqala ihlanganisa ama-antihistamine amasha, angashintshwa abe imithamo ephezulu uma kudingeka. Eminye imithi efana nama-antihistamine amadala, ama-H2 blockers, ama-leukotriene receptor antagonists, ama-antihistamine anamandla, kanye nezifundo ezimfushane ze-corticosteroids zingangezwa njengokwesekwa okwengeziwe. Ezimeni lapho i-urticaria iqhubeka naphezu kwalezi zinyathelo, iziguli zingase zidluliselwe kochwepheshe ukuze bathole ukwelashwa okwengeziwe okufana nokuthi omalizumab noma cyclosporine.
Urticaria commonly presents with intensely itchy raised welts. It is sometimes accompanied by swelling of the underlying tissues. Treatment primarily involves avoiding triggers, if known. First-line medication includes newer antihistamines, which can be adjusted to higher doses if needed. Other medications like older antihistamines, H2 blockers, leukotriene receptor antagonists, stronger antihistamines, and short courses of corticosteroids can be added as extra support. In cases where urticaria persists despite these measures, patients might be referred to specialists for additional therapies such as omalizumab or cyclosporine.

Lokhu kubuyekezwa kuveza imihlahlandlela yakamuva yokwelapha i-urticaria futhi kunikeza ukuqonda okusha kwezimbangela zayo.
This review outlines the latest guidelines for treating urticaria and offers new understandings of its causes.

Second-generation H1-antihistamines (e.g., cetirizine, loratadine, fexofenadine), Omalizumab, Ciclosporin, and short courses only of systemic corticosteroids